BIOMAT Database Logo BIOMAT Database Logo

Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours. 1996

M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg, Sweden.

Neopterin is a marker of the activation of cell-mediated immunity. The aim was to determine whether the concentrations of neopterin differ in plasma, ascites and ovarian cyst fluid between patients with ovarian cancer and patients with benign ovarian tumours. Neopterin was measured in 29 patients with cystic ovarian tumours of unknown histology. 14 ovarian cancers and 15 benign ovarian tumours were diagnosed histologically. Patient age and tumour size did not differ significantly between the groups. Neopterin levels were determined in plasma, and in ascites and cyst fluid by ELISA. The neopterin concentration in plasma, ascites and ovarian cyst fluid was significantly higher in patients with ovarian cancer compared with patients with benign ovarian tumours of the same size. The study shows that activation of cell-mediated immunity, defined as increased formation of neopterin, was increased in patients with ovarian cancer compared with patients with benign ovarian tumours.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010048 Ovarian Cysts General term for CYSTS and cystic diseases of the OVARY. Corpus Luteum Cyst,Corpus Luteum Cysts,Cyst, Corpus Luteum,Cyst, Ovarian,Cysts, Corpus Luteum,Cysts, Ovarian,Ovarian Cyst
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001201 Ascites Accumulation or retention of free fluid within the peritoneal cavity.

Related Publications

M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
January 2001, Anticancer research,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary.
June 1998, British journal of cancer,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumours and normal ovaries.
February 1990, Clinical science (London, England : 1979),
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Plasma spermine concentrations of patients with benign and malignant tumours of the breast or prostate.
March 1979, Clinica chimica acta; international journal of clinical chemistry,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
January 2010, Neuro endocrinology letters,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Markedly elevated CA19-9 associated with benign ovarian cyst and ascites.
January 2009, BMJ case reports,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Serum CA 125 concentrations in patients with benign ovarian tumours.
June 1994, Journal of surgical oncology,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Cytologic examination of ovarian cyst fluid for the distinction between benign and malignant tumors.
September 1993, Obstetrics and gynecology,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours.
November 1998, Scandinavian journal of clinical and laboratory investigation,
M Haeger, and M Swahn, and M Hahlin, and G Horvath, and A Bengtsson
Serum lipids concentration in women with benign and malignant ovarian tumours.
May 2005, European journal of obstetrics, gynecology, and reproductive biology,
Copied contents to your clipboard!